Advances in prevention of contrast-induced nephropathy after coronary angiography or intervention
-
摘要: 随着冠状动脉介入技术在疾病诊断、评估、治疗中的应用日益广泛，造影剂肾病发病率不断升高。多数情况下造影剂肾病是可逆的，但任其发展会增加肾脏及心血管不良事件的发生率。因此如何有效预防和减少造影剂急性肾损伤的发生、减少高危患者不良事件发生成为现阶段心血管介入诊疗并发症防治研究的热点。结合2018年欧洲心脏协会血运重建指南中造影剂肾病的防治推荐，本文对当前造影剂肾病的危险因素、病理生理机制、早期损伤标志物、防治策略等方面进行梳理与总结。Abstract: With the application of coronary angiography or intervention in the diagnosis, evaluation and treatment of coronary heart diseases, the incidence of contrast induced nephropathy is increasing. The contrast induced nephropathy are reversible in most patients, but it will increase the incidence of renal and cardiovascular adverse events. Therefore, how to effectively prevent and reduce the incidence of contrast induced acute kidney injury and reduce the incidence of adverse events in high-risk patients has become the focus of the current researches. According to the recommendations for the prevention and treatment of contrast nephropathy in the 2018 guidelines of the European Heart Association, this paper reviewed and summarized the current research progress in the prevention and treatment of the contrast induced nephropathy.
-
Key words:
- contrast-induced nephropathy /
- contrast media /
- acute kidney injury /
- coronary disease
-
[1] Abe M, Morimoto T, Nakagawa Y, et al. Impact of transient or persistent contrast-induced nephropathy on long-term mortality after elective percutaneous coronary intervention[J]. Am J Cardiol, 2017, 120(12): 2146-53. doi: 10.1016/j.amjcard.2017.08.036 [2] Zheng X, Curtis JP, Hu S, et al. Coronary catheterization and percutaneous coronary intervention in China: 10-year results from the China PEACE-Retrospective CathPCI study[J]. JAMA Intern Med, 2016, 176(4): 512-21. doi: 10.1001/jamainternmed.2016.0166 [3] Makris K, Spanou L. Acute kidney injury: diagnostic approaches and controversies[J]. Clin Biochem Rev, 2016, 37(4): 153-75. [4] Solomon R, Dauerman HL. Acute kidney injury[J]. Circ Cardiovasc Interv, 2017, 10(1): 69-74. [5] Sato A, Aonuma K, Watanabe M, et al. Association of contrast-induced nephropathy with risk of adverse clinical outcomes in patients with cardiac catheterization: from the CINC-J study[J]. Int J Cardiol, 2017, 227(13): 424-9. [6] Liu YH, Liu Y, Zhou YL, et al. Comparison of different risk scores for predicting contrast induced nephropathy and outcomes after primary percutaneous coronary intervention in patients with ST elevation myocardial infarction[J]. Am J Cardiol, 2016, 117(12): 1896-903. doi: 10.1016/j.amjcard.2016.03.033 [7] Samul W, Turowska A, Kwasiborski PJ, et al. Comparison of safety of radial and femoral approaches for coronary catheterization in interventional cardiology[J]. Med Sci Monit, 2015, 21(7): 1464-8. [8] Atanda AC, Olafiranye O. Contrast-induced acute kidney injury in interventional cardiology: Emerging evidence and unifying mechanisms of protection by remote ischemic conditioning[J]. Cardiovasc Revasc Med, 2017, 18(7): 549-53. doi: 10.1016/j.carrev.2017.06.001 [9] Pancholy MS, Skelding K, Scott T, et al. Effect of access site choice on acute kidney injury after percutaneous coronary intervention[J]. Am J Cardiol, 2017, 120(12): 2141-5. doi: 10.1016/j.amjcard.2017.08.039 [10] Rear R, Bell RM, Hausenloy DJ. Contrast-induced nephropathy following angiography and cardiac interventions[J]. Heart, 2016, 102(8): 638-48. doi: 10.1136/heartjnl-2014-306962 [11] Azzalini L, Vilca LM, Lombardo F, et al. Incidence of contrast-induced acute kidney injury in a large cohort of all-comers undergoing percutaneous coronary intervention: comparison of five contrast media[J]. Int J Cardiol, 2018, 273(2): 69-73. [12] Samadian F, Dalili N, Mahmoudieh L, et al. Contrast-induced Nephropathy: Essentials and concerns[J]. Iran J Kidney Dis, 2018, 12(3): 135-41. [13] Reinstadler SJ, Kronbichler A, Reindl M, et al. Acute kidney injury is associated with microvascular myocardial damage following myocardial infarction[J]. Kidney Int, 2017, 92(3): 743-50. doi: 10.1016/j.kint.2017.02.016 [14] Hossain MA, Costanzo E, Cosentino J, et al. Contrast-induced nephropathy: pathophysiology, risk factors, and prevention[J]. Saudi J Kidney Dis Transpl, 2018, 29(1): 1-9. doi: 10.4103/1319-2442.225199 [15] He X, Yang J, Li L, et al. Atorvastatin protects against contrast-induced nephropathy via anti-apoptosis by the upregulation of Hsp27 in vivo and in vitro[J]. Mol Med Rep, 2017, 15(4): 1963-72. doi: 10.3892/mmr.2017.6251 [16] Gao Z, Han Y, Hu Y, et al. Targeting HO-1 by epigallocatechin-3-gallate reduces contrast-induced renal injury via anti-oxidative stress and anti-inflammation pathways[J]. PLoS One, 2016, 11(2): e0149032-43. doi: 10.1371/journal.pone.0149032 [17] Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization[J]. Eur Heart J, 2019, 40(2): 87-165. doi: 10.1093/eurheartj/ehy394 [18] Kronbichler A, Shin JI, Windpessl M. What is left to prevent contrast-induced acute kidney injury? No difference between low and iso-osmolar contrast media[J]. Int J Cardiol, 2018, 273(2): 94-5. [19] Amin AP, Bach RG, Caruso ML, et al. Association of variation in contrast volume with acute kidney injury in patients undergoing percutaneous coronary intervention[J]. JAMA Cardiol, 2017, 2(9): 1007-12. doi: 10.1001/jamacardio.2017.2156 [20] Mccullough PA, Zhang J, Ronco C. Volume expansion and contrast-induced acute kidney injury[J]. Lancet (London, England), 2017, 389(176): 1277-8. [21] Solomon R. Hydration to prevent acute kidney injury after angiography[J]. Coronary Artery Dis, 2017, 28(8): 629-31. doi: 10.1097/MCA.0000000000000515 [22] Solomon R, Lahoud R. Oral hydration[J]. Coron Artery Dis, 2018, 29(4): 283-5. doi: 10.1097/MCA.0000000000000615 [23] Zhang B, Liang L, Chen WB, et al. The efficacy of Sodium bicarbonate in preventing contrast-induced nephropathy in patients with pre-existing renal insufficiency: a meta-analysis[J]. BMJ Open, 2015, 5(3): e6989-100. [24] Abouzeid S, Mosbah O. Evaluation of different Sodium bicarbonate regimens for the prevention of contrast medium-induced nephropathy[J]. Electron physician, 2016, 8(2): 1973-7. doi: 10.19082/1973 [25] Subramaniam RM, Suarez-Cuervo C, Wilson RF, et al. Effectiveness of prevention strategies for contrast-induced nephropathy: a systematic review and meta-analysis[J]. Ann Intern Med, 2016, 164(6): 406-16. doi: 10.7326/M15-1456 [26] Ma WQ, Zhao Y, Wang Y, et al. Comparative efficacy of pharmacological interventions for contrast-induced nephropathy prevention after coronary angiography: a network meta-analysis from randomized trials[J]. Int Urol Nephrol, 2018, 50(6): 1085-95. doi: 10.1007/s11255-018-1814-0 [27] Katsiki N, Fonseca V, Mikhailidis DP. Contrast-induced acute kidney injury in diabetes mellitus: clinical relevance and predisposing factors. could statins be of benefit?[J] J Diab Complicat, 2018, 32(11): 982-4. [28] Li J, Li Y, Xu B, et al. Short-term rosuvastatin therapy prevents contrast-induced acute kidney injury in female patients with diabetes and chronic kidney disease: a subgroup analysis of the TRACK-D study[J]. J Thorac Dis, 2016, 8(5): 1000-6. doi: 10.21037/jtd.2016.03.26 -
下载:
点击查看大图
图(1)
计量
- 文章访问数: 586
- HTML全文浏览量: 255
- PDF下载量: 10
- 被引次数: 0
